Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Medical technology company Viveve Medical (NASDAQ: VIVE) said on Thursday that it has received 501(k) clearance from the US Food and Drug Administration to expand its manufacturing capacity for its consumable treatment tips.
The expansion will allow the company to strengthen its supply chain to meet market demand and reduce its manufacturing costs.
The treatment tips are used with Viveve's Cryogen-cooled Monopolar Radiofrequency technology.
“We are pleased that the FDA has approved the expansion of our consumable treatment tip manufacturing capabilities. In addition to significant reductions in tip manufacturing costs, the expansion strengthens our supply chain, reduces manufacturing risk, and positions us to support increases in treatment tip demand and utilization,” said Viveve's CEO, Scott Durbin.
Viveve shares rose premarket and are currently trading 12.71% higher after the opening bell at $5.41. Wednesday's closing price was $4.80.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .